S&P 500   3,132.52 (-0.11%)
DOW   27,881.72 (-0.10%)
QQQ   203.90 (-0.08%)
AAPL   268.48 (+0.58%)
FB   200.87 (-0.23%)
MSFT   151.13 (-0.15%)
GOOGL   1,342.89 (+-0.01%)
AMZN   1,739.21 (-0.59%)
GE   11.01 (+0.18%)
T   38.06 (+0.05%)
AMD   39.44 (+1.31%)
ACB   2.52 (-3.82%)
F   9.07 (+0.67%)
NFLX   293.12 (-3.10%)
BAC   33.53 (+0.06%)
GILD   67.08 (+0.22%)
DIS   146.10 (-0.08%)
S&P 500   3,132.52 (-0.11%)
DOW   27,881.72 (-0.10%)
QQQ   203.90 (-0.08%)
AAPL   268.48 (+0.58%)
FB   200.87 (-0.23%)
MSFT   151.13 (-0.15%)
GOOGL   1,342.89 (+-0.01%)
AMZN   1,739.21 (-0.59%)
GE   11.01 (+0.18%)
T   38.06 (+0.05%)
AMD   39.44 (+1.31%)
ACB   2.52 (-3.82%)
F   9.07 (+0.67%)
NFLX   293.12 (-3.10%)
BAC   33.53 (+0.06%)
GILD   67.08 (+0.22%)
DIS   146.10 (-0.08%)
S&P 500   3,132.52 (-0.11%)
DOW   27,881.72 (-0.10%)
QQQ   203.90 (-0.08%)
AAPL   268.48 (+0.58%)
FB   200.87 (-0.23%)
MSFT   151.13 (-0.15%)
GOOGL   1,342.89 (+-0.01%)
AMZN   1,739.21 (-0.59%)
GE   11.01 (+0.18%)
T   38.06 (+0.05%)
AMD   39.44 (+1.31%)
ACB   2.52 (-3.82%)
F   9.07 (+0.67%)
NFLX   293.12 (-3.10%)
BAC   33.53 (+0.06%)
GILD   67.08 (+0.22%)
DIS   146.10 (-0.08%)
S&P 500   3,132.52 (-0.11%)
DOW   27,881.72 (-0.10%)
QQQ   203.90 (-0.08%)
AAPL   268.48 (+0.58%)
FB   200.87 (-0.23%)
MSFT   151.13 (-0.15%)
GOOGL   1,342.89 (+-0.01%)
AMZN   1,739.21 (-0.59%)
GE   11.01 (+0.18%)
T   38.06 (+0.05%)
AMD   39.44 (+1.31%)
ACB   2.52 (-3.82%)
F   9.07 (+0.67%)
NFLX   293.12 (-3.10%)
BAC   33.53 (+0.06%)
GILD   67.08 (+0.22%)
DIS   146.10 (-0.08%)
Log in

NASDAQ:TECH - BIO-TECHNE Stock Price, Forecast & News

$219.68
+0.42 (+0.19 %)
(As of 12/10/2019 04:00 PM ET)
Today's Range
$217.36
Now: $219.68
$222.38
50-Day Range
$200.25
MA: $211.14
$222.00
52-Week Range
$132.75
Now: $219.68
$222.87
Volume5,641 shs
Average Volume114,803 shs
Market Capitalization$8.37 billion
P/E Ratio57.81
Dividend Yield0.58%
Beta1.23
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells biotechnology reagents, instruments, and clinical diagnostic controls worldwide. It operates in three segments: Biotechnology, Protein Platforms, and Diagnostics. The Biotechnology segment offers specialized proteins, such as cytokines and growth factors, immunoassays, antibodies, and related reagents to the biotechnology research community; and in situ hybridization, media, and other cell culture products and reagents. Read More…

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryLife Sciences Tools & Services
SectorMedical
Current SymbolNASDAQ:TECH
CUSIP87837710
Phone612-379-8854

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$714.01 million
Cash Flow$5.98 per share
Book Value$30.78 per share

Profitability

Net Income$96.07 million

Miscellaneous

Employees2,250
Market Cap$8.37 billion
Next Earnings Date2/4/2020 (Estimated)
OptionableOptionable

Receive TECH News and Ratings via Email

Sign-up to receive the latest news and ratings for TECH and its competitors with MarketBeat's FREE daily newsletter.


BIO-TECHNE (NASDAQ:TECH) Frequently Asked Questions

What is BIO-TECHNE's stock symbol?

BIO-TECHNE trades on the NASDAQ under the ticker symbol "TECH."

How often does BIO-TECHNE pay dividends? What is the dividend yield for BIO-TECHNE?

BIO-TECHNE declared a quarterly dividend on Tuesday, October 29th. Shareholders of record on Friday, November 8th will be paid a dividend of $0.32 per share on Friday, November 22nd. This represents a $1.28 dividend on an annualized basis and a yield of 0.58%. The ex-dividend date is Thursday, November 7th. View BIO-TECHNE's Dividend History.

How were BIO-TECHNE's earnings last quarter?

BIO-TECHNE Corp (NASDAQ:TECH) announced its quarterly earnings data on Tuesday, October, 29th. The biotechnology company reported $1.06 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $0.92 by $0.14. The biotechnology company had revenue of $183.24 million for the quarter, compared to analyst estimates of $179.38 million. BIO-TECHNE had a return on equity of 13.36% and a net margin of 12.68%. The firm's quarterly revenue was up 12.4% on a year-over-year basis. During the same period last year, the firm earned $0.98 earnings per share. View BIO-TECHNE's Earnings History.

When is BIO-TECHNE's next earnings date?

BIO-TECHNE is scheduled to release their next quarterly earnings announcement on Tuesday, February 4th 2020. View Earnings Estimates for BIO-TECHNE.

What price target have analysts set for TECH?

6 brokers have issued 12 month price targets for BIO-TECHNE's stock. Their forecasts range from $179.00 to $270.00. On average, they anticipate BIO-TECHNE's share price to reach $220.80 in the next twelve months. This suggests a possible upside of 0.4% from the stock's current price. View Analyst Price Targets for BIO-TECHNE.

What is the consensus analysts' recommendation for BIO-TECHNE?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BIO-TECHNE in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for BIO-TECHNE.

Has BIO-TECHNE been receiving favorable news coverage?

News coverage about TECH stock has been trending somewhat positive recently, InfoTrie Sentiment Analysis reports. InfoTrie rates the sentiment of news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. BIO-TECHNE earned a daily sentiment score of 1.8 on InfoTrie's scale. They also gave press coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View News Stories for BIO-TECHNE.

Are investors shorting BIO-TECHNE?

BIO-TECHNE saw a decline in short interest during the month of November. As of November 15th, there was short interest totalling 464,100 shares, a decline of 21.7% from the October 31st total of 592,400 shares. Based on an average daily volume of 154,900 shares, the days-to-cover ratio is presently 3.0 days. Currently, 1.2% of the shares of the stock are sold short. View BIO-TECHNE's Current Options Chain.

Who are some of BIO-TECHNE's key competitors?

What other stocks do shareholders of BIO-TECHNE own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BIO-TECHNE investors own include Paychex (PAYX), Global Medical REIT (GMRE), Gilead Sciences (GILD), AbbVie (ABBV), General Electric (GE), Thermo Fisher Scientific (TMO), Amgen (AMGN), Celgene (CELG), Crispr Therapeutics (CRSP) and Illumina (ILMN).

Who are BIO-TECHNE's key executives?

BIO-TECHNE's management team includes the folowing people:
  • Mr. Charles R. Kummeth, CEO, Pres & Director (Age 59)
  • Mr. James T. Hippel, Sr. VP of Fin. & CFO (Age 48)
  • Ms. Brenda S. Furlow, Gen. Counsel, Sec. & Chief Compliance Officer (Age 61)
  • Mr. N. David Eansor, Pres of Protein Sciences Segment (Age 58)
  • Mr. Gerry Andros, VP of Sales and Marketing

Who are BIO-TECHNE's major shareholders?

BIO-TECHNE's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Massachusetts Financial Services Co. MA (2.51%), State Street Corp (2.37%), First Trust Advisors LP (1.06%), Riverbridge Partners LLC (1.05%), Conestoga Capital Advisors LLC (0.86%) and Kornitzer Capital Management Inc. KS (0.52%). Company insiders that own BIO-TECHNE stock include Brenda S Furlow, Charles A Dinarello, Charles R Kummeth, Harold J Wiens, James Hippel, John L Higgins, Norman David Eansor, Robert V Baumgartner and Roeland Nusse. View Institutional Ownership Trends for BIO-TECHNE.

Which institutional investors are selling BIO-TECHNE stock?

TECH stock was sold by a variety of institutional investors in the last quarter, including First Trust Advisors LP, Millennium Management LLC, State Street Corp, Man Group plc, Squarepoint Ops LLC, State of Tennessee Treasury Department, Barclays PLC and Kornitzer Capital Management Inc. KS. Company insiders that have sold BIO-TECHNE company stock in the last year include Brenda S Furlow, Charles R Kummeth, Harold J Wiens, James Hippel, John L Higgins, Norman David Eansor and Roeland Nusse. View Insider Buying and Selling for BIO-TECHNE.

Which institutional investors are buying BIO-TECHNE stock?

TECH stock was bought by a variety of institutional investors in the last quarter, including Massachusetts Financial Services Co. MA, Candriam Luxembourg S.C.A., Retirement Systems of Alabama, California Public Employees Retirement System, Ascension Asset Management LLC, Comerica Bank, Summit Creek Advisors LLC and Parametric Portfolio Associates LLC. Company insiders that have bought BIO-TECHNE stock in the last two years include Charles R Kummeth and Robert V Baumgartner. View Insider Buying and Selling for BIO-TECHNE.

How do I buy shares of BIO-TECHNE?

Shares of TECH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is BIO-TECHNE's stock price today?

One share of TECH stock can currently be purchased for approximately $219.97.

How big of a company is BIO-TECHNE?

BIO-TECHNE has a market capitalization of $8.38 billion and generates $714.01 million in revenue each year. The biotechnology company earns $96.07 million in net income (profit) each year or $3.80 on an earnings per share basis. BIO-TECHNE employs 2,250 workers across the globe.View Additional Information About BIO-TECHNE.

What is BIO-TECHNE's official website?

The official website for BIO-TECHNE is http://www.techne-corp.com/.

How can I contact BIO-TECHNE?

BIO-TECHNE's mailing address is 614 MCKINLEY PLACE NE, MINNEAPOLIS MN, 55413. The biotechnology company can be reached via phone at 612-379-8854 or via email at [email protected]


MarketBeat Community Rating for BIO-TECHNE (NASDAQ TECH)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  300 (Vote Outperform)
Underperform Votes:  328 (Vote Underperform)
Total Votes:  628
MarketBeat's community ratings are surveys of what our community members think about BIO-TECHNE and other stocks. Vote "Outperform" if you believe TECH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TECH will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/10/2019 by MarketBeat.com Staff

Featured Article: What is cost of equity?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel